| 摘要 |
PURPOSE:Stereospecific reduction of a keto-aminoacid derivative enables easy production of the titled compound which is used as a synthetic intermediate of erythro-3-(3,4-dihydroxyphenyl)serine derivative which has hypertensive activity. CONSTITUTION:The compound of formula II is obtained by stereospecific reduction of a keto-aminoacid derivative of formula I (R is lower alkyl). The stereospecific reduction is effected, e.g., by catalytic reduction in the presence of a metallic catalyst and chemical reduction with a metal hydride complex. The catalytic reduction of the compound of formula I is carried out by bringing the compound into contact with hydrogen gas in an inert solvent such as water or ethanol in the presence of a catalyst, preferably a platinum catalyst such as platinum oxide or a palladium catalyst such as palladium-carbon. |
